Advertise on podcast: RNA Insights

On this episode of RNA Insights, we talk with Deborah Day Barbara about her experience in academia, industry, and business strategy, as well as her thoughts on the rapidly growing RNA therapeutics industry.  Resources referenced in the episode:  Kary Mullis’s Nobel Prize: https://www.nobelprize.org/prizes/chemistry/1993/mullis/facts/ Johns Hopkins Technology Ventures: https://ventures.jhu.edu/ Gene Logic: http://www.genelogic.com Strategic Diagnostics (now SDIX): https://www.sdix.com/  Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy: https://pmc.ncbi.nlm.nih.gov/articles/PMC10294746/  mRNA: The Fourth Pillar of Pharmaceutical Innovation and Intervention: https://www.advancingrna.com/doc/mrna-the-fourth-pillar-of-pharmaceutical-innovation-and-intervention-0001  Lipid nanoparticle-based strategies for extrahepatic delivery of nucleic acid therapies – challenges and opportunities: https://www.sciencedirect.com/science/article/abs/pii/S0168365924002438 Recent Advances in mRNA-LNP Delivery Systems for Extrahepatic Organs: A Review: https://pubs.acs.org/mpohbp/article-abstract/22/8/4474/3750518/Recent-Advances-in-mRNA-LNP-Delivery-Systems-for  ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients: https://ir.ionis.com/news-releases/news-release-details/zanvastrotm-zilganersen-approved-fda-first-and-only-disease GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data: https://www.gsk.com/en-gb/media/press-releases/gsk-to-advance-mrna-seasonal-flu-vaccine-candidate-to-phase-iii-following-positive-phase-ii-data/  Valerio Therapeutics announces signing of definitive agreements for the acquisition of Etherna Immunotherapies, building a leading platform in targeted RNA, and €40.25 million PIPE financing from new and existing investors: https://valeriotx.com/valerio-therapeutics-announces-signing-of-definitive-agreements-for-the-acquisition-of-etherna-immunotherapies-building-a-leading-platform-in-targeted-rna-and-e40-25-million-pipe-financing-from-new-2/   Music by Ievgen Poltavskyi from Pixabay  Sound Effect by Ribhav Agrawal from Pixabay  Eclipsebio host: Grace Finnell-Gudwien

On this episode of RNA Insights, we talk with Dr. Jeff Coller about discovering how codons relate to mRNA stability,  how codon optimality can help treat genetic diseases, and why science communication is essential to the field of RNA medicine.  Resources referenced in the episode: Sjöberg’s research group’s website: https://www.su.se/english/research/research-catalogue/research-groups/4/britt-marie-sjobergs-research-group  Wickens’s laboratory website: https://wickenslab.biochem.wisc.edu/ Coller’s laboratory website: http://www.collerlab.org/  Co-translational mRNA decay in Saccharomyces cerevisiae: https://pubmed.ncbi.nlm.nih.gov/19701183/  Codon optimality is a major determinant of mRNA stability: https://pubmed.ncbi.nlm.nih.gov/25768907/  More information on Gaucher Disease: https://www.gaucherdisease.org/about-gaucher-disease/what-is/ More information on Dravet Syndrome: https://dravetfoundation.org/what-is-dravet-syndrome/  Coller’s LinkedIn: https://www.linkedin.com/in/jeffcoller/ AMM ASCENT: https://mrnamedicines.org/events/2026-annual-meeting/ 4BaseBio: https://www.4basebio.com/ Opinion | The Science That Turned Lizard Venom Into GLP-1s Is Under Attack (The New York Times) : https://www.nytimes.com/2026/06/20/opinion/glp1-research-science-funding.html  Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA®: https://news.modernatx.com/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-plus-keytruda-met-endpoints-of-rfs-and-dmfs-in-melanoma Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia: https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-reports-topline-results-phase-3-shasta Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA: https://feeds.issuerdirect.com/news-release.html?newsid=4801915282452025&symbol=MRNA    Music by Ievgen Poltavskyi from Pixabay  Sound Effect by Ribhav Agrawal from Pixabay  Eclipsebio host: Grace Finnell-Gudwien

On this episode of RNA Insights, we chat with Dr. Tamar Grossman about her years of experience with ASOs and rare diseases, how she navigates multiple roles at once, and how new technologies are expediting the process of developing individualized RNA-based treatments.  Resources referenced in the episode:  Over-expression of DSCAM and COL6A2 cooperatively generates congenital heart defects: https://pubmed.ncbi.nlm.nih.gov/22072978/  Grossman’s publications: https://www.researchgate.net/profile/Tamar-Grossman-3 Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotide: http://www.molvis.org/molvis/v23/561/ Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen: https://www.sciencedirect.com/science/article/pii/S0171298525000105?via%3Dihub  Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease: https://academic.oup.com/brain/article/144/10/2985/6276430 La Jolla Lab’s website: https://www.lajollalabs.ai/La Jolla Lab's email: [email protected] n-of-1 clinical trial: The ultimate strategy for individualizing medicine?: https://pmc.ncbi.nlm.nih.gov/articles/PMC3118090/  La Jolla Labs, Inc. Announces First Patient Treated with Custom Antisense Therapy GBFsen for familial ALS: https://www.biospace.com/press-releases/la-jolla-labs-inc-announces-first-patient-treated-with-custom-antisense-therapy-gbfsen-for-familial-als  mRNA delivery systems 2.0: Engineering extrahepatic delivery for non-vaccine therapeutics: https://pmc.ncbi.nlm.nih.gov/articles/PMC12719227/  Harnessing RNA base editing for diverse applications in RNA biology and RNA therapeutics: https://pmc.ncbi.nlm.nih.gov/articles/PMC11979053/#Sec9  Women in Bio: https://womeninbio.org/  CEO Sisterhood: https://www.ceosisterhood.com/  Female Founders Fund: https://femalefoundersfund.com/  Music by Ievgen Poltavskyi from Pixabay  Sound Effect by Ribhav Agrawal from Pixabay  Eclipsebio host: Grace Finnell-Gudwien

On this episode of RNA Insights, we chat with Dr. Kristian Baker about the relationship between nonsense-mediated decay and mRNA therapeutics as well as Baker's dual roles in research and science advocacy.  Resources referenced in the episode:  Ectopic RNase E sites promote bypass of 5'-end-dependent mRNA decay in Escherichia coli: https://onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2958.2003.03292.x  In vivo-compatible proximity labeling technologies: https://www.sciencedirect.com/science/article/abs/pii/S1367593126000165 Analysis of Nonsense-Mediated mRNA Decay in Saccharomyces cerevisiae: https://currentprotocols.onlinelibrary.wiley.com/doi/abs/10.1002/0471143030.cb2703s54  Single-Gene Disorders: https://www.ncbi.nlm.nih.gov/books/NBK132154/  Prime editing-installed suppressor tRNAs for disease-agnostic genome editing https://www.nature.com/articles/s41586-025-09732-2  Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome: https://www.cell.com/immunity/fulltext/S1074-7613(26)00075-0  RNA Society Journal: https://www.rnasociety.org/about-the-society/journal/ RNA Society website: https://www.rnasociety.org/ Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine: https://feeds.issuerdirect.com/news-release.html?newsid=5170330895753287&symbol=MRNA City Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi Therapeutics: https://www.citytx.com/news/city-therapeutics-announces-99-5-million-series-b-financing-to-advance-next-generation-rnai-therapeutics  Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU): https://www.novartis.com/news/media-releases/novartis-remind-data-eaaci-show-rhapsido-potential-first-targeted-therapy-chronic-inducible-urticaria-cindu  Music by Ievgen Poltavskyi from Pixabay  Sound Effect by Ribhav Agrawal from Pixabay  Eclipsebio host: Grace Finnell-Gudwien

On this episode of RNA Insights, we chat with Dr. Eckhard Jankowsky about his work with RNA helicases and their impact on health, his transition from academia to Big Pharma, and how the past three decades of RNA therapeutic research will influence the future of RNA medicine.    Resources referenced in the episode:  The DEAH-box protein PRP22 is an ATPase that mediates ATP-dependent mRNA release from the spliceosome and unwinds RNA duplexes: https://pubmed.ncbi.nlm.nih.gov/9582286/   The DExH protein NPH-II is a processive and directional motor for unwinding RNA: https://pubmed.ncbi.nlm.nih.gov/10667799/   Jankowsky’s publications: https://scholar.google.com/citations?hl=en&user=z6F2cuoAAAAJ   More information on DDX3X: https://www.ncbi.nlm.nih.gov/gene/1654   More information on DDX3X syndrome: https://www.ucsf.edu/news/2020/03/416816/scientists-unravel-mystery-rare-genetic-disorder-causes-intellectual-disability  The Viral Protein K7 Inhibits Biochemical Activities and Condensate Formation by the DEAD-box Helicase DDX3X: https://www.sciencedirect.com/science/article/abs/pii/S0022283623003169   Hidden specificity in an apparently non-specific RNA-binding protein: https://pmc.ncbi.nlm.nih.gov/articles/PMC3800043/#S1    International mRNA Health Conference: https://mrna-conference.com/  AIRNA Presents New Preclinical Data on AATD Therapeutic Candidate AIR-001 and Cardiometabolic RNA-Editing Programs at ASGCT: https://airna.com/news/airna-presents-new-preclinical-data-on-aatd-therapeutic-candidate-air-001-and-cardiometabolic-rna-editing-programs-at-asgct/   Therorna to Showcase Clinical-Ready Circular RNA in vivo CAR-T and CircRNA Pipeline at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting: https://www.businesswire.com/news/home/20260511897230/en/Therorna-to-Showcase-Clinical-Ready-Circular-RNA-in-vivo-CAR-T-and-CircRNA-Pipeline-at-the-2026-American-Society-of-Gene-Cell-Therapy-ASGCT-Annual-Meeting   AviadoBio Presents Positive Preclinical Data for AVB-406 Program in Alzheimer’s Disease and Other Tauopathies at ASGCT 2026: https://aviadobio.com/aviadobio-presents-positive-preclinical-data-for-avb-406-program-in-alzheimers-disease-and-other-tauopathies-at-asgct-2026/   Music by Ievgen Poltavskyi from Pixabay  Sound Effect by Ribhav Agrawal from Pixabay  Eclipsebio host: Grace Finnell-Gudwien

Welcome to RNA Insights, an RNA therapeutics podcast hosted by Eclipsebio. Each month, we interview a different expert in the field of RNA and RNA-based medicine about their career and thoughts on the ever-evolving RNA therapeutic space.  On this inaugural episode, we talk with Dr. Gene Yeo, co-developer of the eCLIP protocol and co-founder of Eclipsebio, about his journey identifying the need for and developing a more efficient method of crosslinking immunoprecipitation that changed the ways scientists perform RNA research.  Resources referenced in the episode:  Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals: https://pubmed.ncbi.nlm.nih.gov/15285897/  Identification and analysis of alternative splicing events conserved in human and mouse: https://pubmed.ncbi.nlm.nih.gov/15708978/  Yeo Lab Publications: https://yeolab.com/publications   ENCODE Overview: https://www.encodeproject.org/help/project-overview/   Robust transcriptome-wide discovery of RNA-binding protein binding sites with enhanced CLIP (eCLIP): https://www.nature.com/articles/nmeth.3810  Circio enters in vivo cell therapy evaluation agreement with Acuitas Therapeutics: https://www.circio.com/en/circio-enters-in-vivo-cell-therapy-evaluation-agreement-with-acuitas-therapeutics/  Afrigen Biologics Announces RSV mRNA Vaccine Collaboration: https://www.afrigen.co.za/news-press-release-events/  Immorna Announces First Evidence of Tissue B Cell Depletion with In Vivo CAR T JCXH 213 in Systemic Sclerosis Patient, Underscoring Platform’s Potential to Address Autoimmune Diseases: https://www.immornabio.com/News-details/41.html  Music by Ievgen Poltavskyi from Pixabay  Sound Effect by Ribhav Agrawal from Pixabay  Hosted by Grace Finnell-Gudwien